News Related to IDE849

Related coverage linked through entity extraction aliases.

IDEAYA Biosciences Reports Q4 2025 Results, Awaits Pivotal Uveal Melanoma Trial Data

Mar 11, 2026

IDEAYA Biosciences announced Q4 2025 financial results with $1.05 billion in cash reserves and confirmed 130 progression-free survival events in its Phase 2/3 OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with topline results expected by late March 2026.

Two Biotech Companies Report 2025 Financial Results and Pipeline Progress

Feb 26, 2026

Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.